30 grams of walnuts and almonds per day: what we know about preventing diabetes and heart disease

IN BRIEF

• A metabolomic study conducted on people with metabolic syndrome observed changes in urine after 12 weeks of daily consumption of 30g of mixed nuts (walnuts, almonds, hazelnuts), suggesting alterations in fatty acid, polyphenol, and serotonin metabolism.
• Meta-analyses and clinical trials indicate that the regular inclusion of tree nuts is associated with improved lipid profiles and a reduction in some inflammatory markers; evidence on direct diabetes prevention is more heterogeneous.
• Plausible mechanisms include unsaturated fats, fiber, polyphenols metabolized by the microbiota (urolithins), and possible effects on satiety and the gut microbiome.
• The benefit depends on dose, dietary context, and replacement of other foods: the results should not be interpreted as proof of a unique causal effect.

Abstract: What does science say?

The central question is whether a moderate daily intake of tree nuts—for example, a ~30-gram serving of walnuts, almonds, or hazelnuts—can reduce markers of metabolic risk and, consequently, impact the long-term risk of type 2 diabetes and cardiovascular disease. Available evidence includes short clinical studies with intermediate endpoints (metabolomics, lipid profile, inflammatory indicators), dietary intervention trials in large cohorts (e.g., the nut arm in the Mediterranean trial), and numerous observational and controlled trial meta-analyses. Overall, the data support a favorable role for nuts in improving lipids and some inflammatory markers; the effect on diabetes prevention is less consistent and depends on how nuts are incorporated into the diet (caloric substitution, types of foods removed). Given the mixed nature of the evidence (observational + short trials), interpretive caution is necessary: biological plausibility exists, but evidence of direct causality is limited and depends on study design, duration, and dietary context.

MAIN SECTION

The original data: the University of Barcelona study

A metabolomic investigation conducted by researchers affiliated with the University of Barcelona compared, for 12 weeks, patients with metabolic syndrome who consumed 30 g daily of a nut mix (walnuts, almonds, and hazelnuts) with a control group that avoided nuts. The study used non-targeted techniques to analyze metabolic changes in urine and reported an increase in metabolites related to fatty acid metabolism, signs of increased excretion of serotonin derivatives, and the appearance of microbial metabolites derived from nut polyphenols (urolithins). These observations indicate biochemical alterations consistent with metabolic effects and a possible role of the microbiota in processing substances present in nuts [1].

Plausible biological mechanisms

Several elements of nuts can contribute to plausible beneficial effects: profiles rich in unsaturated fatty acids (particularly n-3 and n-6 in walnuts), dietary fiber, plant proteins, and polyphenols such as ellagitannins. Ellagitannins can be transformed by the gut microbiota into urolithins, compounds with anti-inflammatory and antioxidant activity demonstrated in experimental models [2]. Furthermore, replacing foods rich in refined carbohydrates or saturated fats with nuts can improve the lipid profile and reduce systemic inflammation, as shown in meta-analyses and controlled trials [3]. However, it is essential to distinguish plausibility from proof of efficacy for major clinical events.

What clinical and observational evidence shows

Meta-analyses of prospective cohorts and clinical trials provide a complex picture. Meta-analyses and systematic reviews show inverse associations between regular nut consumption and the risk of cardiovascular events and overall cardiovascular mortality [7]. A large randomized lifestyle trial (PREDIMED) observed a reduction in cardiovascular events in an arm that included supplementation with a nut mix compared to the control, albeit within the context of a broader dietary intervention [4]. Specific studies on walnuts have documented favorable effects on the gut microbiota and some microbial bile acids, with possible metabolic implications [5]. Meta-analyses of controlled clinical trials referring to intermediate markers (cholesterol, triglycerides, fasting glucose, HbA1c) show modest but consistent improvements for some parameters [3][6]. A more recent review that summarized observational and trial data confirmed an overall favorable association but highlighted heterogeneity and limitations in demonstrating a direct causal relationship [8].

PRACTICAL SECTION

What it means in practice

For the reader, the practical message is that regularly including moderate portions of oily nuts in an overall balanced diet is plausibly beneficial for cardiometabolic profile. Evidence suggests improvements in plasma lipids, reductions in some inflammatory markers, and metabolic changes consistent with potential benefits. However, these effects manifest within an overall dietary context: benefits emerge more clearly when nuts replace foods high in refined sugars or saturated fats, not simply when added to the diet without caloric compensation [3][4][7]. The use of nuts as part of healthy eating patterns (e.g., Mediterranean diet) therefore appears to be the most evidence-supported approach [4][7].

Dose, frequency, and form of consumption

In clinical literature, the frequently studied portion is about 30 g per day, which corresponds to a small handful. The metabolomic study on subjects with metabolic syndrome adopted this amount for 12 weeks [1]. Many observational meta-analyses indicate that significant benefits can already emerge with average intakes of 15–30 g/day, but the dose-response relationship may not be linear and depends on how nuts replace other foods in the diet [7][8]. Preferring unsalted nuts and consuming them whole (not necessarily as butter or sweetened) preserves fiber, unsaturated fats, and polyphenols useful for the described effects [3][5].

KEY POINTS TO REMEMBER

• Metabolomic research shows that 12 weeks with 30 g/day of nuts produce observable metabolic changes in people with metabolic syndrome; these signals are useful but do not automatically equate to a reduction in clinical events [1].
• The components of nuts — unsaturated fats, fiber, and polyphenols — offer biological plausibility for positive effects on lipids, inflammation, and microbiota [2][3][5].
• Randomized trials integrated into broader dietary interventions and observational meta-analyses agree on a favorable association with cardiovascular outcomes, but the strength of the evidence varies for diabetes and some glycemic markers [4][6][7][8].
• The benefits depend on the dose, the way they are incorporated into the diet, and the caloric replacement effect; there is no single dietary 'cure'.
• Interpret the results with caution: metabolic observations and improvements in intermediate markers are encouraging, but do not replace long-term studies with definitive clinical endpoints.

LIMITATIONS OF THE EVIDENCE

The evidence collected comes from different types of studies, each with distinct limitations. Observational studies show associations between nut consumption and a lower risk of cardiovascular events, but they can be influenced by residual confounders (lifestyle, education, overall diet quality) that are not always fully controlled [7][8]. The available clinical trials are often short-term and measure intermediate endpoints (cholesterol, inflammation, urinary metabolites), so their ability to prove long-term effects on the onset of diabetes or major cardiovascular events is limited [1][3][6]. There is also heterogeneity in the type of nuts studied (walnuts vs. almonds vs. hazelnuts), in the doses, and in the method of dietary integration, which makes it difficult to generalize specific results. Finally, individual variability in the microbiota can modulate the formation of active metabolites (urolithins) and thus the observable biological effect [2][5]. For all these reasons, interpretive caution is essential; long-term randomized studies and analyses clarifying the role of dietary substitution are needed.

Editorial Conclusion

The body of research accumulated over several decades suggests that the regular introduction of oily dried fruit into the diet, in moderate portions (around 30 g/day), can contribute to improving certain cardiometabolic risk factors thanks to a combination of unsaturated fats, fiber, biologically active compounds, and interactions with the microbiota. The evidence comes from metabolomic studies, short- and medium-term clinical trials, and large observational cohorts: together, they offer a plausible basis for considering dried fruit as part of a healthy diet. However, this is not a therapeutic prescription nor definitive proof of diabetes or heart disease prevention if consumed in isolation. Nutritional recommendations should always consider the individual clinical picture, the overall dietary composition, and possible allergies. Pending longer and more targeted studies, the moderate integration of unsalted dried fruit into a healthy eating pattern appears to be a choice supported by the literature.

EDITORIAL NOTE

This article is an update of previously published content. The update is based on a critical review of peer-reviewed scientific sources, with particular attention to the methodological quality of the studies and the transparency of the sources (including verified DOIs). The material is for informational purposes only and does not replace personalized medical advice.

SCIENTIFIC RESEARCH

1. Tulipani S, Llorach R, Jáuregui O, López‑Uriarte P, Garcia‑Aloy M, Bullo M, Salas‑Salvadó J, Andrés‑Lacueva C. Metabolomics Unveils Urinary Changes in Subjects with Metabolic Syndrome following 12‑Week Nut Consumption. Journal of Proteome Research. 2011;10(11):5047–5058. https://doi.org/10.1021/pr200514h
2. Tulipani S, Garcia‑Villalba R, Monagas M, et al. Urolithins Are the Main Urinary Microbial‑Derived Phenolic Metabolites Discriminating a Moderate Consumption of Nuts in Free‑Living Subjects with Diagnosed Metabolic Syndrome. Journal of Agricultural and Food Chemistry. 2012;60(36):8930–8940. https://doi.org/10.1021/jf301509w
3. Banel DK, Hu FB. Effects of walnut consumption on blood lipids and other cardiovascular risk factors: a meta‑analysis and systematic review. American Journal of Clinical Nutrition. 2009;90(1):56–63. https://doi.org/10.3945/ajcn.2009.27457
4. Estruch R, Ros E, Salas‑Salvadó J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. New England Journal of Medicine. 2013;368:1279–1290. https://doi.org/10.1056/NEJMoa1200303
5. Holscher HD, Davis SR, Timm DA, et al. Walnut Consumption Alters the Gastrointestinal Microbiota, Microbially Derived Secondary Bile Acids, and Health Markers in Healthy Adults: A Randomized Controlled Trial. The Journal of Nutrition. 2018;148(6):861–869. https://doi.org/10.1093/jn/nxy004
6. Viguiliouk E, Kendall CW, Blanco Mejia S, et al. Effect of Tree Nuts on Glycemic Control in Diabetes: A Systematic Review and Meta‑Analysis of Randomized Controlled Dietary Trials. PLoS ONE. 2014;9(7):e103376. https://doi.org/10.1371/journal.pone.0103376
7. Zhang X, Huang X, Wu J, et al. Nut consumption and incidence of cardiovascular diseases and cardiovascular disease mortality: a meta‑analysis of prospective cohort studies. BMC Medicine. 2016;14:207. https://doi.org/10.1186/s12916-016-0730-3
8. Arnesen EK, Thorisdottir B, Barebring L, et al. Nuts and seeds consumption and risk of cardiovascular disease, type 2 diabetes and their risk factors: a systematic review and meta‑analysis. Food & Nutrition Research. 2023;67:8961. https://doi.org/10.29219/fnr.v67.8961